Corporate Presentation

Bringing hope to people living with Neurodegenerative Diseases
This presentation has been prepared by Alpha Cognition Inc. ("ACI" or the "Company"). This presentation includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements include statements regarding the Company’s business strategy, future plans, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the technology. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements as a result of known and unknown risks, uncertainties, assumptions and other factors. These risks include those associated with clinical studies and manufacturing; risks around development and commercialization of the Company’s products; the need for additional financing to maintain operations; risks posed by the economic and political environments in which the Company operates and intends to operate; market instability due to the COVID-19 pandemic; the potential for losses arising from the expansion of operations into new markets; increased competition; assumptions regarding market trends and the expected demand and desires for the Company’s products and proposed products; reliance on industry manufacturers, suppliers and key personnel; the failure to adequately protect intellectual property; a failure to adequately manage future growth; adverse market conditions; and failure to satisfy ongoing regulatory requirements or obtain regulatory approvals. These forward-looking statements speak only as of the date of this presentation and, other than as required by applicable securities laws, the Company undertakes no obligation to revise or update any forward-looking statements, even if new information becomes available in the future.

This presentation includes industry and market data that we obtained from periodic industry publications, third-party studies and surveys, filings of public companies in our industry, patient and disease advocacy educational sites and internal company surveys. These sources include government and industry sources. Industry publications and surveys generally state that the information contained therein has been obtained from sources believed to be reliable and reasonable. Although we believe the industry and market data to be reliable as of the date of this presentation, this information could prove to be inaccurate. Industry and market data could be wrong because of the method by which sources obtained their data and because information cannot always be verified with complete certainty due to the limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other limitations and uncertainties. In addition, we do not know all of the assumptions regarding general economic conditions or growth that were used in preparing the forecasts from the sources relied upon or cited herein. The projections, assumptions and estimates of the future performance of the markets in which we operate and our future performance are necessarily subject to uncertainty and risk due to a variety of factors. These and other factors could cause results to differ materially from those expressed in the estimates made by third parties and by us.

ALL CURRENCIES DENOTED ARE IN UNITED STATES DOLLARS UNLESS OTHERWISE INDICATED
Commercial and R&D Biopharmaceutical Company Focused On Neurodegenerative Diseases

ZUNVEYL® – Differentiated Treatment Potential for Alzheimer’s Disease

1. Large US 11M annual prescription (Rx) market characterized by high drug dissatisfaction and discontinuation
2. Oral therapy uniquely designed to reduce side effects and improve long term patient outcomes
3. Long Term Care (LTC) represents approximately 36% of annual prescription and provides an estimated, potential initial commercial opportunity ($2B) with future expansion to Neurology (27% of annual prescription, $1.5B)

Pipeline to expand treatments for Alzheimer’s Disease

• ZUNVEYL approved for treatment of mild-to-moderate Alzheimer’s disease (AD) July 26, 2024
• ALPHA-1062 sublingual tablet to treat AD patients with aphagia in pre-clinical development
• ALPHA-1062 combination product to treat AD patients with moderate-to-severe disease in pre-clinical development
• Patent protection granted through 2042 with additional patent filing approval expected in 2024

Experienced Leadership Team - History Of Multi-Billion Drug Launches

• Management team has been involved over 20 product launches and over 25 approvals in the USA and Europe for other companies
• Excellent commercial experience in Long Term Care (LTC)
• Multiple billion dollar drug launches (CELEBREX™, CRESTOR™, NEXIUM™, SEROQUEL™) by leadership team

1. Symphony METYS Retail 2019; Includes donepezil, galantamine, rivastigmine and Namzaric
2. Symphony METYS Retail 2019; Average WAC prices from Access Pointe Managed Markets Market Research
3. Estimated based on US$11 million annual prescriptions x LTC percentage of prescriptions (36%) x average WAC price of $500
4. Estimated based on US$11 million annual prescriptions x Neurology percentage of prescriptions (27%) x average WAC price of $500
5. Prescription Drug User Free Act
Alzheimer’s Disease Has Significant Treatment Challenges And High Drug Discontinuation

Alzheimer’s Disease (AD) is a type of dementia that causes a slow decline in memory, thinking and reasoning. AD therapy represents a significant US market with high dissatisfaction, primarily due to adverse events and limited efficacy over time.

**Significant Market**
- AD Impacts nearly 7M people in the U.S.¹
- 40% of life after AD spent in Long Term Care Facility with severe disease¹
- 11 million prescriptions written annually to treat AD and 80% of patients prescribed Acetylcholinesterase Inhibitors (AChE’s)²,³

**Unmet Medical Need**
- 72% of MD’s are dissatisfied with treatments mainly due to medication side effects⁴
- 55% of patients discontinue current medications therapy at 12 months³

---

¹ Alzheimer's Association 2024 Facts and Figures
² Clarivate DRG Market Forecast Assumptions Dashboard
³ Data on File Symphony METYS Retail 2019
⁴ Data on File Market Research, Affinity Group July 2021
ZUNVEYL: Uniquely Designed Prodrug Of Galantamine

Potential treatment designed to optimize efficacious dose, minimize treatment-limiting side-effects and improve long-term outcomes

The formation of the benzoyl ester eliminates AChE inhibition; the gluconate salt increases solubility.

ZUNVEYL is absorbed in the small intestine as an inactive compound with minimal or no side effects.

ZUNVEYL is subject to 1st pass effect, cleaving the benzoyl ester, resulting in the release of galantamine (active moiety).

Galantamine, the metabolite, may circulate with greater bioavailability (ability to be absorbed and used by the body).
Galantamine (ZUNVEYL’s Active Moiety) Enhances Acetylcholine Levels And Modulates Nicotinic Receptor Sensitivity

Decreased acetylcholine levels and loss of nicotinic acetylcholine receptors (nAChR) negatively impacts learning, memory, and function

Current therapeutics\(^1\) increase acetylcholine levels by inhibiting acetylcholinesterase (AChE)

**Modulation of nAChR (α7/α4β2)\(^2\):**
- Stimulates the cholinergic pathway
- Modulates inflammation
- Buffers the effects of amyloid
- Enhances release of other transmitters: Glu, DA, GABA, 5HT - resulting in enhanced:
  - Memory acquisition and retrieval
  - Attention and activity
  - Stabilization of behavior
  - Inhibition of cell death and neuroprotection

\(^1\) Excluding Memantine for moderate-to-severe Alzheimer’s disease
\(^2\) Lilienfeld, S. (2002) CNS Drug Reviews, 8(2), 159-176
Alpha Cognition’s Oral Therapy ZUNVEYL Has Received FDA Approval To Treat Alzheimer's Disease

**INDICATION:** ZUNVEYL (benzgalantamine) is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults.

The Second Oral Therapy Approved This Decade, ZUNVEYL’s Dual MOA Was Designed to Eliminate Drug Absorption in the Gastrointestinal (GI) Tract, Potentially Addressing Certain Tolerability Issues with Leading Alzheimer’s Disease (AD) Medications, Combined with a Long-Term Efficacy Profile
Zunveyl’s Differentiated Profile Will Make A Meaningful Difference In The Lives Of Those Affected By Alzheimer’s Disease

There is a significant need for better treatment options

- Current treatment options can have significant side effects, including gastrointestinal and insomnia issues leading to discontinuation.
- Physicians report feeling dissatisfied and/or apathetic about their symptomatic treatment options.³
- Caregivers also express dissatisfaction with the currently approved symptomatic treatments options.³

<table>
<thead>
<tr>
<th>GI Safety Profile</th>
<th>Reduced GI side-effects (diarrhea, nausea, vomiting)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNS Safety Profile</td>
<td>No incidence of insomnia</td>
</tr>
<tr>
<td>Long Term Outcome¹</td>
<td>Significant risk reduction in risk of developing severe dementia</td>
</tr>
<tr>
<td>Cognition Effects</td>
<td>Demonstrated strongest effect on cognition</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>Dual mechanisms of action that potentiate acetylcholine transmission and modulate nACh R (α7/α4β2)²</td>
</tr>
</tbody>
</table>

¹Xu et al. Neurology 96 (17) e2221 (2021)
³Data on File, Infinity Group, HCP and Caregiver Market Research, July 2021

* Rivastigmine is also available as a transdermal patch
ZUNVEYL Was Designed To Eliminate Drug Absorption In The GI Tract And Has Zero Incidence Of Insomnia

**ACHEIs Activity** In The GI Nervous System Overstimulates Local Neurons Resulting In Side-Effects

- **0% incidence of insomnia** in ZUNVEYL label

  “…Accumulating evidence shows that sleep disturbance contributes to cognitive decline.”

  “Galantamine may be the first choice of cholinesterase inhibitor in mild to moderate dementia patients in terms of improving sleep quality.”

---

Galantamine (Zunveyl’s Active Moiety) Reduces Risk Of Disease Progression And Has The Strongest Effect On Cognition

- Galantamine affects multiple brain receptors to exert effect
- Galantamine has demonstrated anti-inflammation effects\(^1\)
- Galantamine has been associated with:\(^1,2\)
  - Improved Memory and Attention
  - Significantly lower risk of death (P-value <0.001)
  - Strongest AChEI effect on cognitive decline
  - Demonstrates significant reduction in risk of developing severe dementia (P-value 0.05) compared to donepezil (P-value 0.13) and rivastigmine (P-value 0.24)
- Use of Galantamine reduces nursing home admission by 31% per year of treatment\(^3\)

\(^1\) Lilienfeld, S. (2002) CNS Drug Reviews, 8(2), 159-176
\(^2\) Xu et al. Neurology 96 (17) e2221 (2021)
Multiple AD Launches Have Achieved Billion Dollar Yearly Sales

- Large US 11M annual prescription market characterized by high drug dissatisfaction and discontinuation
- Multiple successful launches into the AD space
- Significant brand sales despite generic competition
- Exelon Patch *(above graph)* achieved $650M in peak sales in fully generic market on promise of lower gastrointestinal adverse events

<table>
<thead>
<tr>
<th>Product</th>
<th>Peak Sales (in B)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Namenda</td>
<td>$1.8</td>
</tr>
<tr>
<td>Namenda XR</td>
<td>$1.25</td>
</tr>
<tr>
<td>Namzaric</td>
<td>$0.270</td>
</tr>
<tr>
<td>Aricept</td>
<td>$2.6</td>
</tr>
<tr>
<td>Exelon</td>
<td>$0.650</td>
</tr>
<tr>
<td>Razadyne</td>
<td>$0.250</td>
</tr>
</tbody>
</table>

Despite No Differentiation, NAMZARIC, 505(b)(2) Treatment For Moderate-To-Severe Alzheimer’s Delivers +$200M In Yearly Sales

NAMZARIC Sales by Year ($M)

- NAMZARIC provides base case for sales for a new symptomatic entrant into the Alzheimer’s (AD) market
- 505(b)(2) pathway with no differentiation versus generics
- Moderate-to-severe AD is 33% smaller potential than mild-to-moderate AD
- Launched May 2015; No promotion since 2018
- ~75% of MA lives have access to NAMZARIC\(^1\) with Average co-pay of $50.00-$67.50\(^1\)
- Average retail price of $667.74\(^1\)

\(^1\)Source = National Sales Perspectives

Promotion Stopped
AChEI’s Market Large But Dissatisfied Creating Opportunity For Improved Treatment Option, Specifically In Long Term Care (LTC)

- Large, but dissatisfied market creates significant market opportunity
  - 11M AChEI RX’s dispensed each year\(^1\)
  - High discontinuation rates due to side-effects

- Initial go-to-market commercial footprint to focus on highest volume, most favorable market access conditions
  - LTC accounts for 36% of total market Rx’s\(^2\)
  - LTC provides estimated, potential initial commercial opportunity ($2B potential)\(^3\) with future expansion to Neurology ($1.5B potential)\(^4\)
  - Branded medications used more commonly in LTC market
  - 65-70% of LTC lives have access to ZUNVEYL with zero co-pay

\(^1\) Symphony METYS Retail 2019: Includes donepezil, galantamine, rivastigmine and Namzaric
\(^2\) Symphony METYS Retail 2019; Average WAC prices from Access Pointe Managed Markets Market Research
\(^3\) Estimated based on US$11 million annual prescriptions x LTC percentage of prescriptions (36%) x average WAC price of $50
\(^4\) Estimated based on US$11 million annual prescriptions x Neurology percentage of prescriptions (27%) x average WAC price of $500
Alzheimer’s Dementia Affects 70% Long Term Care (LTC) Residents And 88% LTC Doctors Likely To Prescribe

6.7M
Americans living with Alzheimer’s Disease (AD)¹

5.4M
Americans living with mild-to-moderate AD³

1.2M
Americans living in nursing homes⁴

LTC represent ~13% of the AD population but delivers 36% of the market

Large, Underserved LTC Market

In Nursing Homes, Alzheimer’s Dementia:
• Affects 70% residents¹
• Is the leading reason for placement¹
• Is the leading cause of death¹

Significant Dissatisfaction with Current Treatments Leads to ZUNVEYL Opportunity

• Current treatment options cause burden for staff and risks for residents due to GI side effects and insomnia²
• 55% patients discontinue their AD medication due to side effects²
• Market research indicates ~88% of LTC HCPs Likely to prescribe ZUNVEYL²

1. Alzheimer’s Association Facts and Figures - 2023
2. Data on File - LTC Market Research, October 2021
Commercialization Strategy Will Leverage Expected Differentiated Profile And Focused Sales Effort At Launch

Commercial leadership intends to build an excellent LTC sales force with the following focus:

- Potential key points of differentiation
- Exploit key issues with existing AChEi treatments
- Franchise with potential additional indications and new products

Success to be further enabled by:

- Targeting largest volume nursing homes/geriatricians specializing in Alzheimer’s Dementia
- Experienced, account-based sales team with demonstrated success in LTC
- Limited payor barriers with 70% of residents
- Strategic and clinical partnerships with Consultant Pharmacists and LTC Pharmacies
ZUNVEYL Alzheimer's Dementia Opportunity

Large but Dissatisfied Market

LTC represents largest AD prescription volume

>50% discontinue treatment at 12 months

88% LTC HCPs potentially willing to prescribe

ZUNVEYL Potential

Potential Reduced Adverse Event Profile

Delayed Progression of Disease

Strongest effect on cognition

Additional Clinical Development Programs

ZUNVEYL sublingual tablet pre-clinical stage

DOD Bomb-blast study results expected Q4

Near-term Milestones

ZUNVEYL Pricing
Q4 2024

New Composition of Matter Patent
expected approval Q4 2024

ZUNVEYL Commercial Launch
Q1 2025

COPYRIGHT 2021 ALPHA COGNITION, INC.*Market size determined by estimated branded price X market TRX for drug market basket used to treat mild-moderate AD
<table>
<thead>
<tr>
<th>Indication</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3 /Pivotal</th>
<th>Approved</th>
<th>Entity Responsible</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ZUNVEYL (ALPHA-1062)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral: Mild-to-Moderate Alzheimer’s Disease (AD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><img src="alpha_cognition.png" alt="Alpha Cognition" /></td>
</tr>
<tr>
<td>Sublingual Formulation: Mild-to-Moderate Alzheimer’s Disease (AD)¹</td>
<td></td>
<td><img src="alpha_cognition.png" alt="Alpha Cognition" /></td>
<td><img src="alpha_cognition.png" alt="Alpha Cognition" /></td>
<td><img src="alpha_cognition.png" alt="Alpha Cognition" /></td>
<td><img src="alpha_cognition.png" alt="Alpha Cognition" /></td>
<td><img src="alpha_cognition.png" alt="Alpha Cognition" /></td>
</tr>
<tr>
<td><strong>ALPHA-1062 Intranasal (Partnered Asset)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><img src="alpha_seven.png" alt="Alpha Seven Therapeutics" /></td>
</tr>
<tr>
<td>Cognitive Impairment with Mild Traumatic Brain Injury¹,²</td>
<td></td>
<td><img src="alpha_seven.png" alt="Alpha Seven Therapeutics" /></td>
<td><img src="alpha_seven.png" alt="Alpha Seven Therapeutics" /></td>
<td><img src="alpha_seven.png" alt="Alpha Seven Therapeutics" /></td>
<td><img src="alpha_seven.png" alt="Alpha Seven Therapeutics" /></td>
<td><img src="alpha_seven.png" alt="Alpha Seven Therapeutics" /></td>
</tr>
</tbody>
</table>

1. Contingent on sufficient capital to be raised
2. Alpha Seven Therapeutics was incorporated in Delaware in July 2023. The out-license of ZUNVEYLIN technology has not yet occurred.
Potential Catalysts And Upcoming Events

**2024**
- ✔ Composition of Matter IP filing – US/Rest of World (Q1)
- ✔ ZUNVEYL anticipated FDA product approval (Q3)
- □ Composition of Matter IP approval – US (Q4)
- □ DOD Sponsored Bomb-blast study results (preclinical) (Q4)

**2025**
- □ ZUNVEYL commercial launch (1Q)
- □ IND Submission for Cognitive Impairment with mTBI – Alpha Seven
- □ Zunveyl + Memantine initiation of clinical trial (Q4)
Leadership Has Impressive Track Record For Successful New Drug Development And Commercialization

Michael McFadden
Chief Executive Officer

Denis Kay
Chief Scientific Officer

Lauren D'Angelo, MBA
Chief Operating Officer

Don Kalkofen
Chief Financial Officer
### Share Structure

<table>
<thead>
<tr>
<th>ACOG.CN, ACOGF</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Share Price (as of June 23, 2024)</td>
<td>$0.88 CAD / $0.64 USD</td>
</tr>
<tr>
<td>Market Cap (as of June 23, 2024)</td>
<td>$133M CAD / $96M USD</td>
</tr>
</tbody>
</table>

#### June 13, 2024

<table>
<thead>
<tr>
<th></th>
<th>Issued and Outstanding</th>
<th>% of total</th>
<th>Proforma Outstanding (1)</th>
<th>% of total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Shares</td>
<td>150,605,536</td>
<td>61.0%</td>
<td>7,530,277</td>
<td>61.0%</td>
</tr>
<tr>
<td>Class B Preferred Series A Shares</td>
<td>7,916,380</td>
<td>3.2%</td>
<td>395,819</td>
<td>3.2%</td>
</tr>
<tr>
<td>Performance Shares</td>
<td>6,641,057</td>
<td>2.7%</td>
<td>332,053</td>
<td>2.7%</td>
</tr>
<tr>
<td>Non-Trading Warrants</td>
<td>61,232,886</td>
<td>24.8%</td>
<td>3,061,644</td>
<td>24.8%</td>
</tr>
<tr>
<td>Stock Options</td>
<td>20,399,367</td>
<td>8.3%</td>
<td>1,019,968</td>
<td>8.3%</td>
</tr>
<tr>
<td><strong>TOTAL ALL SHARES</strong></td>
<td><strong>246,795,226</strong></td>
<td><strong>100.0%</strong></td>
<td><strong>12,339,761</strong></td>
<td><strong>100.0%</strong></td>
</tr>
</tbody>
</table>

(1) Proforma shares are based on the contemplated 1 for 20 reverse stock split, which is contingent on the Company’s Nasdaq listing.

---

1. CSE and OTC markets do not always trade at currency differentiation.